Status:
COMPLETED
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
Lead Sponsor:
Solvay Pharmaceuticals
Collaborating Sponsors:
H. Lundbeck A/S
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophr...
Eligibility Criteria
Inclusion
- Subjects with the current Diagnosis of Schizophrenia, Bipolar Type I Disorder according to DSM-IV TR criteria
- Age 18 to 55
- Body weight 100-250 lbs
- Be sufficiently stable to allow discontinuation of antipsychotic medication
Exclusion
- Acutely psychotic subjects
- Subjects that are acutely manic
- Subjects with a psych diagnosis other than Bipolar Type I Disorder
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00139919
Start Date
January 1 2006
End Date
October 1 2007
Last Update
January 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 1
Orange, California, United States